Expert Opinion on Emerging Drugs

Papers
(The H4-Index of Expert Opinion on Emerging Drugs is 11. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
Aticaprant: (a κ-opioid receptor antagonist) for major depressive disorder66
Emerging drugs in phase II and III clinical development for the treatment of alcohol use disorder22
Expert opinion on emerging drugs for lung chronic graft-versus-host disease20
Emerging drugs for the treatment of hepatocellular carcinoma19
Emerging drugs for hemophilia A: insights into phase II and III clinical trials17
Recent advances in uveitis therapy: focus on selected phase 2 and 3 clinical trials14
Emerging drugs for the treatment of major depressive disorder13
Emerging drugs for the treatment of type 1 diabetes mellitus: a review of phase 2 clinical trials13
Emerging therapeutics in Huntington’s disease12
Emerging drugs for antibody-mediated rejection after kidney transplantation: a focus on phase II & III trials12
Emerging drugs for the treatment of paroxysmal nocturnal hemoglobinuria11
Emerging drugs for the acute treatment of relapses in adult neuromyelitis optica spectrum disorder patients11
0.030281066894531